Mark G. Carmichael

687 total citations
24 papers, 558 citations indexed

About

Mark G. Carmichael is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark G. Carmichael has authored 24 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 9 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark G. Carmichael's work include Immunotherapy and Immune Responses (15 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and vaccines and immunoinformatics approaches (6 papers). Mark G. Carmichael is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and vaccines and immunoinformatics approaches (6 papers). Mark G. Carmichael collaborates with scholars based in United States, Germany and Greece. Mark G. Carmichael's co-authors include Sathibalan Ponniah, Jeremy D. Gates, Jarrod P. Holmes, George E. Peoples, Linda C. Benavides, Elizabeth A. Mittendorf, Matthew T. Hueman, Dianna Craig, Alexander Stojadinovic and Asna Amin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Mark G. Carmichael

22 papers receiving 541 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark G. Carmichael United States 11 421 373 226 223 34 24 558
Karuna Sundarapandiyan United States 11 355 0.8× 180 0.5× 185 0.8× 279 1.3× 22 0.6× 18 506
Ulf Forssmann Germany 11 207 0.5× 152 0.4× 189 0.8× 104 0.5× 56 1.6× 24 409
Tsin Yee Tai Australia 12 593 1.4× 275 0.7× 263 1.2× 62 0.3× 13 0.4× 21 724
Hyun Tae Lee South Korea 8 204 0.5× 323 0.9× 125 0.6× 154 0.7× 49 1.4× 10 513
Victoria Zakhaleva United States 7 242 0.6× 289 0.8× 223 1.0× 74 0.3× 62 1.8× 9 487
Szilvia Mosolits Sweden 12 334 0.8× 247 0.7× 148 0.7× 93 0.4× 24 0.7× 15 478
Elia Neninger Cuba 12 370 0.9× 453 1.2× 238 1.1× 135 0.6× 157 4.6× 34 661
Hilde Omholt Norway 6 579 1.4× 384 1.0× 131 0.6× 44 0.2× 20 0.6× 7 689
Annaelisa Tasciotti Italy 8 199 0.5× 222 0.6× 103 0.5× 176 0.8× 43 1.3× 13 435
Annie Galinha France 15 435 1.0× 187 0.5× 343 1.5× 354 1.6× 14 0.4× 26 718

Countries citing papers authored by Mark G. Carmichael

Since Specialization
Citations

This map shows the geographic impact of Mark G. Carmichael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Carmichael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Carmichael more than expected).

Fields of papers citing papers by Mark G. Carmichael

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Carmichael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Carmichael. The network helps show where Mark G. Carmichael may publish in the future.

Co-authorship network of co-authors of Mark G. Carmichael

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Carmichael. A scholar is included among the top collaborators of Mark G. Carmichael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Carmichael. Mark G. Carmichael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Desmond, Daniel & Mark G. Carmichael. (2018). Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review.. PubMed. 77(2). 27–29. 1 indexed citations
2.
Benavides, Linda C., Jeremy D. Gates, Guy T. Clifton, et al.. (2011). Comparison of different HER2/neuvaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Review of Vaccines. 10(2). 201–210. 19 indexed citations
3.
Perez, Sonia A., Guy T. Clifton, Linda C. Benavides, et al.. (2011). AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opinion on Biological Therapy. 11(11). 1543–1550. 37 indexed citations
4.
Shumway, Nathan M., et al.. (2011). Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.. Journal of Clinical Oncology. 29(15_suppl). 564–564. 2 indexed citations
5.
Shumway, Nathan M., Mark G. Carmichael, Jarrod P. Holmes, et al.. (2011). Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER2/neu peptide vaccine trial.. Journal of Clinical Oncology. 29(15_suppl). e11126–e11126. 1 indexed citations
6.
Gates, Jeremy D., Guy T. Clifton, Linda C. Benavides, et al.. (2010). Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine. 28(47). 7476–7482. 31 indexed citations
7.
Benavides, Linda C., Jeremy D. Gates, Mark G. Carmichael, et al.. (2009). The Impact of HER2/neuExpression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clinical Cancer Research. 15(8). 2895–2904. 99 indexed citations
8.
Clifton, Guy T., Jarrod P. Holmes, Asna Amin, et al.. (2009). Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial. Journal of the American College of Surgeons. 210(2). 140–147. 38 indexed citations
9.
Gates, Jeremy D., Mark G. Carmichael, Linda C. Benavides, et al.. (2009). Longterm Followup Assessment of a HER2/ neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients. Journal of the American College of Surgeons. 208(2). 193–201. 16 indexed citations
10.
Carmichael, Mark G., Linda C. Benavides, Jarrod P. Holmes, et al.. (2009). Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients. Cancer. 116(2). 292–301. 82 indexed citations
11.
Holmes, Jarrod P., Jeremy D. Gates, Linda C. Benavides, et al.. (2008). Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence. Cancer. 113(7). 1666–1675. 46 indexed citations
12.
13.
Holmes, Jarrod P., Linda C. Benavides, Jeremy D. Gates, et al.. (2008). Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine. Journal of Clinical Oncology. 26(20). 3426–3433. 112 indexed citations
14.
Gates, Jeremy D., Linda C. Benavides, Alexander Stojadinovic, et al.. (2008). Monitoring circulating tumor cells in cancer vaccine trials. Human Vaccines. 4(5). 389–392. 8 indexed citations
15.
Collen, Jacob, et al.. (2008). Metastatic Malignant Teratoma Arising from Mediastinal Nonseminomatous Germ Cell Tumor: A Case Report. Military Medicine. 173(4). 406–409. 4 indexed citations
16.
Benavides, Linda C., Jarrod P. Holmes, Jeremy D. Gates, et al.. (2008). Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03. Journal of Clinical Oncology. 26(15_suppl). 3016–3016. 1 indexed citations
17.
18.
Kwok, N. M., et al.. (2007). Statistical decision based gray-level image feature matching. UTS ePRESS (University of Technology Sydney). 1 indexed citations
19.
20.
Carmichael, Mark G., et al.. (2003). A 59-Year-Old Woman with Tuberculous Meningitis Masked by Hepatic Encephalopathy. Military Medicine. 168(3). 266–269.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karuna Sundarapandiyan Breakdown of academic impact, for papers by Ulf Forssmann Breakdown of academic impact, for papers by Tsin Yee Tai Breakdown of academic impact, for papers by Hyun Tae Lee Breakdown of academic impact, for papers by Victoria Zakhaleva Breakdown of academic impact, for papers by Szilvia Mosolits Breakdown of academic impact, for papers by Elia Neninger Breakdown of academic impact, for papers by Hilde Omholt Breakdown of academic impact, for papers by Annaelisa Tasciotti Breakdown of academic impact, for papers by Annie Galinha
Rankless by CCL
2026